参考文献
|
-
Huang, SS,Chang, CC(2019).Comparison of insight in patients with schizophrenia, bipolar I disorder, and major depressive disorder in a real-world setting.Taiwan J Psychiatry,33,92-98.
連結:
-
Alphs, L,Bossie, CA,Sliwa, JK(2013).Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.Neuropsychiatr Dis Treat,9,341-350.
-
Birnbaum, M,Sharif, Z(2008).Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER.Patient Prefer Adherence,2,233-240.
-
Chi, MH,Hsiao, CY,Chen, KC(2016).The readmission rate and medical cost of patients with schizophrenia after first hospitalization – a 10-year follow-up population-based study.Schizophr Res,170,184-190.
-
Chiang, CL,Chen, PC,Huang, LY(2016).Impact of universal health coverage on urban-rural inequity in psychiatric service utilisation for patients with first admission for psychosis: a 10-year nationwide population-based study in Taiwan.BMJ Open,6,e010802.
-
Fu, DJ,Turkoz, I,Simonson, RB(2016).Paliperidone palmitate once-monthly injectable treatment for acute exacerbations of schizoaffective disorder.J Clin Psychopharmacol,36,372-376.
-
Fu, DJ,Turkoz, I,Simonson, RB(2015).Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.J Clin Psychiatry,76,253-262.
-
Jin, H,Mosweu, I(2017).The societal cost of schizophrenia: a systematic review.Pharmacoeconomics,35,25-42.
-
Kishimoto, T,Nitta, M,Borenstein, M(2013).Long-acting injectableversus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.J Clin Psychiatry,74,957-965.
-
Lêng, CH,Chou, MH,Lin, SH(2016).Estimation of life expectancy, loss-of-life expectancy, and lifetime healthcare expenditures for schizophrenia in Taiwan.Schizophr Res,171,97-102.
-
Lo, TL,Warden, M,He, Y(2016).Recommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region.Asia Pac Psychiatry,8,154-171.
-
Malla, A,Tibbo, P,Chue, P(2013).Long-acting injectable antipsychotics: recommendations for clinicians.Can J Psychiatry,58,30S-35S.
-
Millier, A,Schmidt, U,Angermeyer, MC(2014).Humanistic burden in schizophrenia: a literature review.J Psychiatr Res,54,85-93.
-
Olivares, JM,Thirunavukarasu, M,Kulkarni, J(2013).Psychiatrists’ awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-pacific survey.Neuropsychiatr Dis Treat,9,1163-1170.
-
Pan, YJ,Kuo, KH,Yeh, LL(2019).Healthcare cost, service use and mortality in major psychiatric disorders in Taiwan.J Affect Disord,246,112-120.
-
Samalin, L,Abbar, M,Courtet, P(2013).French society for biological psychiatry and neuropsychopharmacology task force: formal consensus for the prescription of depot antipsychotics.Encephale,39(Suppl 4),189-203.
-
Schreiner, A,Bergmans, P,Cherubin, P(2015).Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.J Psychopharmacol,29,910-922.
-
Su, KP,Chang, HC,Tsai, SJ(2009).Relapse and long-acting injectablerisperidone: a 1-year mirror image study with a national claims database in Taiwan.Value Health,12(Suppl 3),118-121.
-
Taipale, H,Mehtälä, J,Tanskanen, A(2018).Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-A nationwide study with 20-year follow-up.Schizophr Bull,44,1381-1387.
-
Tiihonen, J,Mittendorfer-Rutz, E,Majak, M(2017).Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia.JAMA Psychiatry,74,686-693.
-
Turkoz, I,Fu, DJ,Bossie, CA(2015).The direct and indirect effects of paliperidone extended-release on depressive symptoms in schizoaffective disorder: a path analysis.Innov Clin Neurosci,12,10-17.
-
Wallwork, RS,Fortgang, R,Hashimoto, R(2012).Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia.Schizophr Res,137,246-250.
-
Zhang, F,Si, T,Chiou, CF(2015).Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia.Neuropsychiatr Dis Treat,11,657-668.
-
Zhang, H,Turkoz, I,Zhuo, J(2017).Paliperidone palmitate improves and maintains functioning in Asia-pacific patients with schizophrenia.Adv Ther,34,2503-2517.
|